Eli Lilly's Omvoh sustains UC efficacy and safety for four years

Eli Lilly and Company has released new findings showing Omvoh (mirikizumab-mrkz) is the first and only interleukin-23p19 (IL-23p19), used for the treatment of moderately to severely active ulcerative colitis (UC) to report sustained, long-term outcomes over four years.

The results were shown across a range of symptomatic, clinical, endoscopic, histological and quality-of-life measures, including in patients who had initially failed a biologic or advanced therapy (27%).

"Helping people with ulcerative colitis achieve long-term comprehensive disease control is a major goal for gastroenterologists, as it has remained out of reach for many patients," said Bruce Sands, M.D., M.S., Dr. Burrill B. Crohn Professor of Medicine and Chief of the Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai.

Also Read: Advanced Formulation Technologies Streamlining Global Pharma Innovation

"With these results, Omvoh continues to set a high standard as the first and only IL-23p19 with evidence of sustained efficacy and consistent safety in ulcerative colitis over four years," said Mark Genovese, M.D., senior vice president of Lilly Immunology development.

This data is the final results from the LUCENT-3 Phase 3 open-label extension study, and will be shared at United European Gastroenterology (UEG) Week, held Oct. 4-7 in Berlin. Long-term safety with moderately to severely active UC was consistent with the established safety profile of Omvoh, while no new safety signals were identified. 12% of patients completed one year of blinded Omvoh maintenance therapy in LUCENT-2 and transitioned to LUCENT-3 reported a serious adverse event, while 7% discontinued treatment due to an adverse event.

Omvoh has received regulatory approvals for adults in moderate to severe active ulcerative colitis and moderate to severe active Crohn's disease and is authorized for use in 44 countries around the world.